Pressmeddelande -
GU Ventures welcomes and appoints Eduarde Rohner as Lead for New Modality Support
As of November 1, Eduarde Rohner is the Lead for New Modality Support (NMS), a forward-looking initiative in collaboration with the Sahlgrenska Academy, the medical faculty at the University of Gothenburg, and the Sahlgrenska University Hospital. The aim is to support the commercial development of research projects within the national pharmaceutical initiatives OligoNova and CCRM Nordic.
Eduarde Rohner, who holds a PhD in Medical Sciences, brings extensive experience in the development of stem cell and mRNA therapies, where he has contributed to advancing therapeutic assets from early discovery to preclinical proof-of-concept. In his previous role as Senior Scientist at SmartCella Solutions, Eduarde also established landscape analysis and strategies for patentability.
- "I am pleased to have been appointed Lead for NMS. This role allows me to leverage my experience gained from managing projects within stem cell and mRNA therapies, as well as from my research conducted during my doctoral studies at the Karolinska Institute, in a new context. I look forward to working with our partners and the NMS team to create new and competitive global companies", says Eduarde Rohner.
- “Eduarde brings valuable experience and a strong network to develop and commercialize individual research projects within NMS, which offers support and serves as a platform of expertise as projects transition from academic research to clinical application”, says Carl-Peter Mattsson, Investment Director at GU Ventures and Strategic Coordinator for NMS.
About New Modality Support (NMS)
NMS supports the further development and commercialization of individual research projects within the therapeutic oligonucleotide and ATMP sectors. By combining the experience and resources of participating parties with new, sector-specific expertise, value-creating services can be developed and deployed more efficiently. Additionally, as a platform that promotes networking and highlights both the research and commercialization efforts, NMS enhances opportunities for projects and companies to attract investments and partnerships.
NMS is located at GoCo Health Innovation City in Mölndal and is supported by both the Västra Götaland Region through the Environment and Regional Development Board, as well as by the University of Gothenburg and GU Ventures. This support enables GU Ventures, the coordinator for NMS, to work strategically and sustainably towards the project´s success.
For more information, please visit:
Ämnen
Kategorier
Om GU Ventures AB
GU Ventures bygger företag av banbrytande idéer som kan forma en bättre morgondag och är topprankad av UBI Global Index som en av världens 20 ledande universitetsdrivna inkubatorer. Vi finansierar och utvecklar nya innovativa affärsidéer med kopplingar till Göteborgs universitet, som är ett av norra Europas största universitet. Vårt uppdrag är att kommersialisera dessa innovationer, så att det leder till användning av forskning och kompetens, förnyelse av näringslivet, skapande av jobb och hållbar tillväxt. Vårt passionerade team av företagsbyggare, finansexperter, IP och juridisk talang supporterar dedikerat våra företag och säkerställer deras framgång.
Sedan startpunkten 1995 har GU Ventures utvecklat över 240 nya affärsidéer, varav 140 bedriver verksamhet idag och varav 15 är listade. Vår portfölj består av 80-tal innehav och ett antal projekt.
I den senaste undersökningen matchar 87% av företagen de globala hållbarhetsmål som ställts av FN. GU Ventures ägs helt av den svenska staten och förvaltas av Göteborgs universitet. Läs gärna mer på: www.guventures.com.
